Forbion
Forbion Ventures Fund VIII + Growth Opportunities Fund IV
Forbion is a Dutch life-sciences investor with more than 140 portfolio companies. Its largest raise to date brings €2.3B across two vehicles: Ventures Fund VIII for pre-clinical and early clinical therapeutics companies, including new company creation, and Growth Opportunities Fund IV for later-stage, crossover and public biopharma positions in Europe and North America. The raise beat its target, lifts AUM to about €7.5B, and was backed by Eli Lilly, KfW Capital, PGGM, MN and the Kauffman Foundation.
Fund size
€2.3B
combined
Closed
Oct 6
2026 · final close
Check size
Members
min and max cheque
Stage
Members
and regions of investment
Focus
BiotechSeedSeries AGrowthLate stage
Who to email
1 person · each checked 2026-10-25Sander Slootweg
Managing Partner and Co-founder
Names and roles from the fund's own team page. Contact details are the ones the firm publishes. Listed here and want out? Remove my profile.
Sources
- BioSpace, 2026-10-07
- forbion.com, checked 2026-10-25